Theratechnologies develops therapies for unmet medical needs in commercially attractive specialty markets.

Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

In the clinic


Tesamorelin:
Completed Phase 3 clinical studies evaluating tesamorelin in HIV-associated lipodystrophy.

Find out more on the study

 

 

Products

Our lead product: tesamorelin

A New Drug Application was filed with the U.S. Food and Drug Administration in order to obtain market approval for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.

More...

Investors


See our investor kit:

2008 Annual Report

Quarterly Report

Corporate Presentation

 

 


 

News

  • January 25, 2010 - Theratechnologies reports that the FDA will reschedule for administrative reasons the Advisory Committee meeting to review tesamorelin’s NDA More...
  • January 18, 2010 - Theratechnologies reports date for FDA Advisory Committee Review of the Tesamorelin New Drug Application More...
  • January 11, 2010 - Theratechnologies to present at Biotech Showcase 2010 More...

Events

  • From January 12 to 13, 2010 - Biotech Showcase 2010 More...